These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 21444233)
41. Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics. Sharma P; Scott DG Drugs; 2015 Nov; 75(17):1953-6. PubMed ID: 26474779 [TBL] [Abstract][Full Text] [Related]
42. Subcutaneous methotrexate to cut costs? Hassanzadeh R; Mangan C; France J; Bawa S J Rheumatol; 2012 Aug; 39(8):1764-5. PubMed ID: 22859538 [No Abstract] [Full Text] [Related]
43. Disease modifying treatment for feline rheumatoid arthritis. Hanna FY Vet Comp Orthop Traumatol; 2005; 18(2):94-9. PubMed ID: 16594204 [TBL] [Abstract][Full Text] [Related]
44. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Hamilton RA; Kremer JM Br J Rheumatol; 1997 Jan; 36(1):86-90. PubMed ID: 9117183 [TBL] [Abstract][Full Text] [Related]
45. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Knevel R; Schoels M; Huizinga TW; Aletaha D; Burmester GR; Combe B; Landewé RB; Smolen JS; Sokka T; van der Heijde DM Ann Rheum Dis; 2010 Jun; 69(6):987-94. PubMed ID: 20448280 [TBL] [Abstract][Full Text] [Related]
46. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477 [TBL] [Abstract][Full Text] [Related]
47. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA; Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767 [TBL] [Abstract][Full Text] [Related]
48. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Québec, Canada. Bernatsky S; Ehrmann Feldman D Drugs Aging; 2008; 25(10):879-84. PubMed ID: 18808212 [TBL] [Abstract][Full Text] [Related]
50. Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial. Häuselmann HJ; Caravatti M; Seifert B; Wang K; Bruckner P; Stucki G; Michel BA Br J Rheumatol; 1998 Oct; 37(10):1110-7. PubMed ID: 9825751 [TBL] [Abstract][Full Text] [Related]
51. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Klareskog L; van der Heijde D; de Jager JP; Gough A; Kalden J; Malaise M; Martín Mola E; Pavelka K; Sany J; Settas L; Wajdula J; Pedersen R; Fatenejad S; Sanda M; Lancet; 2004 Feb; 363(9410):675-81. PubMed ID: 15001324 [TBL] [Abstract][Full Text] [Related]
52. Methotrexate: still the anchor drug in RA treatment. Bijlsma JW; Jacobs JW Joint Bone Spine; 2009 Oct; 76(5):452-4. PubMed ID: 19560956 [No Abstract] [Full Text] [Related]
53. Methotrexate: a gold standard for treatment of rheumatoid arthritis. Shinde CG; Venkatesh MP; Kumar TM; Shivakumar HG J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):351-8. PubMed ID: 25322199 [TBL] [Abstract][Full Text] [Related]
54. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Willkens RF; Sharp JT; Stablein D; Marks C; Wortmann R Arthritis Rheum; 1995 Dec; 38(12):1799-806. PubMed ID: 8849352 [TBL] [Abstract][Full Text] [Related]
55. [Portuguese recommendations for the use of methotrexate in the treatment of rheumatoid arthritis]. Canhão H; Santos MJ; Costa L; Bogas M; Mourão AF; Machado P; Fonseca JE; Silva JA; Acta Reumatol Port; 2009; 34(1):78-95. PubMed ID: 19377402 [TBL] [Abstract][Full Text] [Related]
56. Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials. Parker CT; Mewshaw E; Dennis GJ J Am Osteopath Assoc; 2004 Jan; 104(1):7-8. PubMed ID: 14992316 [No Abstract] [Full Text] [Related]
57. When should we use parenteral methotrexate? Mainman H; McClaren E; Heycock C; Saravanan V; Hamilton J; Kelly C Clin Rheumatol; 2010 Oct; 29(10):1093-8. PubMed ID: 20544244 [TBL] [Abstract][Full Text] [Related]
58. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Bakker MF; Jacobs JW; Welsing PM; van der Werf JH; Linn-Rasker SP; van der Veen MJ; Lafeber FP; Bijlsma JW; Ann Rheum Dis; 2010 Oct; 69(10):1849-52. PubMed ID: 20511610 [TBL] [Abstract][Full Text] [Related]